BD BBL™ Sensi-Disc™ Erythromycin 15 µg 231290Recalls & reported problems
Becton, Dickinson And Company · BD BBL™ Sensi-Disc™ Erythromycin 15 µg · Class 2
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 30382902312902), received between Feb 18, 2025 and Feb 18, 2025 — classified as 2 malfunctions.
The most frequently reported specific device problem is “Incorrect, Inadequate or Imprecise Result or Readings” (2 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Reports received per month
Most reported problems
Device problems
- Incorrect, Inadequate or Imprecise Result or Readings2
Patient problems
- No Clinical Signs, Symptoms or Conditions2
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
MalfunctionFeb 18, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings
IT WAS REPORTED WHILE USING THE BD BBL¿ SENSI-DISC¿ ERYTHROMYCIN 15G A PATIENT ISOLATE TESTED SENSITIVE, SHOWING A CLEAR NO-GROWTH ZONE AROUND THE DISC FOR THE DRUG ERYTHROMYCIN, BUT WHEN COMPARED TO THE INSTRUMENTATION RESULT IT WAS RESISTANT. NO HEALTH IMPACT OR CONSEQUENCE REPORTED. REPORT 2 OF 2.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 21395932 ↗MalfunctionFeb 18, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings
IT WAS REPORTED WHILE USING THE BD BBL¿ SENSI-DISC¿ ERYTHROMYCIN 15G A PATIENT ISOLATE TESTED SENSITIVE, SHOWING A CLEAR NO-GROWTH ZONE AROUND THE DISC FOR THE DRUG ERYTHROMYCIN, BUT WHEN COMPARED TO THE INSTRUMENTATION RESULT IT WAS RESISTANT. NO HEALTH IMPACT OR CONSEQUENCE REPORTED. REPORT 1 OF 2.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 21395322 ↗
Other SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL devices
- BD BBL Sensi-Disc Ampicillin 2 ug 231263Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL2 recalls0 reports
- BD BBL™ Sensi-Disc™ Ciprofloxacin 5 µg 231658Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall2 reports
- BD BBL™ Sensi-Disc™ Piperacillin/Tazobactam 100/10 µg 231691Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Ceftazidime 30 µg 231633Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Levofloxacin 5 µg 231706Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Cefepime 30 µg 231696Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Chloramphenicol 30 µg 231274Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall0 reports
- BD BBL™ Sensi-Disc™ Cefotaxime 30 µg 231607Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall0 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page